Exposure-response analysis of alemtuzumab in pediatric allogeneic HSCT for nonmalignant diseases: the ARTIC study

Alemtuzumab (anti-CD52 antibody) is frequently prescribed to children with nonmalignant diseases undergoing allogeneic hematopoietic stem cell transplantation (HSCT) to prevent graft failure (GF) and acute graft-versus-host disease (aGVHD). The aim of this multicenter study was the characterization...

Descripción completa

Detalles Bibliográficos
Autores principales: Achini-Gutzwiller, Federica R., Schilham, Marco W., von Asmuth, Erik G. J., Jansen-Hoogendijk, Anja M., Jol-van der Zijde, Cornelia M., van Tol, Maarten J. D., Bredius, Robbert G. M., Güngör, Tayfun, Lankester, Arjan C., Moes, Dirk Jan A. R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Transplantation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10440472/
https://www.ncbi.nlm.nih.gov/pubmed/37285798
http://dx.doi.org/10.1182/bloodadvances.2022009051

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10440472/
https://www.ncbi.nlm.nih.gov/pubmed/37285798
http://dx.doi.org/10.1182/bloodadvances.2022009051

Ejemplares similares